248 related articles for article (PubMed ID: 28212584)
1. Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy.
Edelman R; Assaraf YG; Levitzky I; Shahar T; Livney YD
Oncotarget; 2017 Apr; 8(15):24337-24353. PubMed ID: 28212584
[TBL] [Abstract][Full Text] [Related]
2. Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer.
Edelman R; Assaraf YG; Slavkin A; Dolev T; Shahar T; Livney YD
Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31060303
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma.
Journo-Gershfeld G; Kapp D; Shamay Y; Kopeček J; David A
Pharm Res; 2012 Apr; 29(4):1121-33. PubMed ID: 22350800
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel loaded hyaluronic acid nanoparticles for targeted cancer therapy: in vitro and in vivo analysis.
Thomas RG; Moon M; Lee S; Jeong YY
Int J Biol Macromol; 2015 Jan; 72():510-8. PubMed ID: 25224289
[TBL] [Abstract][Full Text] [Related]
5. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery.
Liu Y; Sun J; Cao W; Yang J; Lian H; Li X; Sun Y; Wang Y; Wang S; He Z
Int J Pharm; 2011 Dec; 421(1):160-9. PubMed ID: 21945183
[TBL] [Abstract][Full Text] [Related]
7. One-pot preparation of hyaluronic acid-coated iron oxide nanoparticles for magnetic hyperthermia therapy and targeting CD44-overexpressing cancer cells.
Soleymani M; Velashjerdi M; Shaterabadi Z; Barati A
Carbohydr Polym; 2020 Jun; 237():116130. PubMed ID: 32241421
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment.
Song Y; Cai H; Yin T; Huo M; Ma P; Zhou J; Lai W
Int J Nanomedicine; 2018; 13():1585-1600. PubMed ID: 29588586
[TBL] [Abstract][Full Text] [Related]
9. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.
Lee SJ; Ghosh SC; Han HD; Stone RL; Bottsford-Miller J; Shen DY; Auzenne EJ; Lopez-Araujo A; Lu C; Nishimura M; Pecot CV; Zand B; Thanapprapasr D; Jennings NB; Kang Y; Huang J; Hu W; Klostergaard J; Sood AK
Clin Cancer Res; 2012 Aug; 18(15):4114-21. PubMed ID: 22693353
[TBL] [Abstract][Full Text] [Related]
10. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid.
Yin S; Huai J; Chen X; Yang Y; Zhang X; Gan Y; Wang G; Gu X; Li J
Acta Biomater; 2015 Oct; 26():274-85. PubMed ID: 26300335
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers.
Gawde KA; Sau S; Tatiparti K; Kashaw SK; Mehrmohammadi M; Azmi AS; Iyer AK
Colloids Surf B Biointerfaces; 2018 Jul; 167():8-19. PubMed ID: 29625422
[TBL] [Abstract][Full Text] [Related]
12. Dual CD44 and folate receptor-targeted nanoparticles for cancer diagnosis and anticancer drug delivery.
Lee JY; Termsarasab U; Park JH; Lee SY; Ko SH; Shim JS; Chung SJ; Cho HJ; Kim DD
J Control Release; 2016 Aug; 236():38-46. PubMed ID: 27320169
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.
Ganesh S; Iyer AK; Morrissey DV; Amiji MM
Biomaterials; 2013 Apr; 34(13):3489-502. PubMed ID: 23410679
[TBL] [Abstract][Full Text] [Related]
14. Development and mechanistic insight into enhanced cytotoxic potential of hyaluronic acid conjugated nanoparticles in CD44 overexpressing cancer cells.
Saneja A; Nayak D; Srinivas M; Kumar A; Khare V; Katoch A; Goswami A; Vishwakarma RA; Sawant SD; Gupta PN
Eur J Pharm Sci; 2017 Jan; 97():79-91. PubMed ID: 27989859
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid/polyethylene glycol nanoparticles for controlled delivery of mitoxantrone.
Sargazi A; Kamali N; Shiri F; Heidari Majd M
Artif Cells Nanomed Biotechnol; 2018 May; 46(3):500-509. PubMed ID: 28503952
[TBL] [Abstract][Full Text] [Related]
16. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
17. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer.
Zhang W; Xu W; Lan Y; He X; Liu K; Liang Y
Int J Nanomedicine; 2019; 14():5287-5301. PubMed ID: 31406460
[No Abstract] [Full Text] [Related]
19. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting.
Song S; Qi H; Xu J; Guo P; Chen F; Li F; Yang X; Sheng N; Wu Y; Pan W
Pharm Res; 2014 Nov; 31(11):2988-3005. PubMed ID: 24842660
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
